TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 42nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 94nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 137nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 204nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 216nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 240nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 250nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 358nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 450nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 476nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 487nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 610nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.36E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 2.23E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 2.49E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 2.51E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 2.82E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 3.73E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 3.83E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 4.91E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 6.20E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 6.40E+3nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The dose dependent inhibition of OCT2 mediated uptake of a model substrate 14C-Tetraethylammonium (TEA) by test compounds was studied in wild-type an...More data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 5.00E+4nMAssay Description:Inhibition of OCT2 (unknown origin) expressed in HEK293 cellsMore data for this Ligand-Target Pair
TargetPOU domain, class 2, transcription factor 2(Homo sapiens (Human))
Gilead Sciences, Inc.
US Patent
Gilead Sciences, Inc.
US Patent
Affinity DataIC50: 8.00E+4nMAssay Description:Inhibition of OCT2 (unknown origin) expressed in HEK293 cells assessed as reduction of [14C]metformin substrate uptake at 100 uM by liquid scintillat...More data for this Ligand-Target Pair